Dragonfly Therapeutics, Inc.’s Post

Congratulations to Joseph E. Eid and his team for the Dragonfly Therapeutics, Inc. recent partnership with Gilead Sciences. Drug Name : DF-1001 Dragonfly Therapeutics, Inc., a clinical stage biotechnology company developing novel immunotherapies announced a new clinical collaboration designed to evaluate and combine DF1001, a HER-2 immune engager developed using Dragonfly's TriNKET technology platform and Dragonfly's lead clinical asset, with Trodelvy, Gilead's Trop-2-directed antibody drug conjugate (ADC), in metastatic breast cancer (mBC) and non-small cell lung cancer (NSCLC). "DF1001 is the first of eight Dragonfly-developed drugs in the clinic and has shown clinical benefit in mBC, NSCLC and colorectal cancer (CRC) in a heterogeneous Phase 1 population with 22% RECIST responders and 39% clinical benefit in mBC patients at active dose levels, with no DLTs, even in a heavily-pre-treated population," said Joseph Eid, Dragonfly President of R&D. "It has been demonstrated to be well tolerated across all dose levels in the Phase 1 study as monotherapy, and pharmacodynamic activity was demonstrated in 28/42 (67%) paired biopsies from 0.5-15mg/kg, where increase in CD8 and NK cell infiltration was observed consistent with preclinical models and supporting the TriNKET immune modulating MoA. Our preclinical work has shown the powerful combinatorial effect of TriNKETs with ADCs, and highlighted the potential benefits to patients of using Gilead's Trodelvy in combination with DF1001."

Another fascinating research article delving into advancements in treatment of small-cell lung cancer! This research article depicts advances in small-cell lung cancer (SCLC) treatment target DLL3, an inhibitory ligand. The authors elaborated that while Rova-T didn’t succeed in trials, tarlatamab is showing great promise and is now under FDA review. With innovative approaches like BiTEs, CAR T-cell therapies, and radiotherapy in the pipeline, DLL3-targeted therapies could significantly improve SCLC outcomes. #CancerResearch #SCLC #Biotech #HealthcareInnovation

This new Nature article regarding ADCs is worth reading. The author, Benjamin Plackett interviewed a few ADC experts and KOLs including the prestigious Kyoji Tsuchikama and Timothy Lowinger to discuss in this insightful article how to balance potency with toxicity and tackle the cost of next-generation ADCs. By the way, Antibody Therapeutics (2023 CiteScore: 8.7), the officially journal of Chinese Antibody Society, published by Oxford University Press, calls for papers in “Antibody-Drug Conjugates for Cancer Treatment”. You are welcome to submit your ADC manuscripts for this special collection by August 31, 2024. You may know more detailed information from the link below to the website of call for papers announcement. https://lnkd.in/g_Ck_q2z #antibodies #antibody #antibodytherapeutics #mabs #mab #antibodydiscovery #adc #adcs #antibodydrugconjugates #antibodydrugconjugate

🌟 Major Step Forward in Cancer Treatment: Angiex has officially dosed the first patient in its Phase 1 trial of a novel ADC (antibody-drug conjugate) therapy. 💉 This trial marks an important milestone in the development of targeted cancer therapies, potentially offering a new lifeline for patients facing tough-to-treat cancers. As Angiex continues to advance this promising therapy, the biopharma industry is watching closely. 🔍 #ClinicalTrials #CancerTreatment #ADCTherapy #Biopharma #OncologyInnovation 🔗 Explore the details of this exciting trial and its potential impact on cancer care: https://lnkd.in/e5JSkJHA

Elicio Therapeutics, a clinical-stage biotech firm, unveiled encouraging preliminary data from its AMPLIFY-7P Phase 1a study of ELI-002 7P, an investigational cancer vaccine targeting mKRAS-driven solid tumors. The study found ELI-002 7P was well-tolerated and generated robust T cell responses against multiple KRAS mutations, correlating with reduced tumor biomarkers at the recommended Phase 2 dose. 'These early immunogenicity and biomarker response data from ELI-002 7P continue to provide encouraging results showing that our lymph node-targeted approach generates a robust and differentiated T cell response that strongly correlates with tumor biomarker reductions,' said Christopher Haqq, MD, PhD, executive vice president and head of R&D at @eliciotherapeutics. The findings demonstrated ELI-002 7P's potential to address the high unmet need in treating KRAS-mutated tumors, which account for 25% of solid tumors and have limited treatment options. The data was presented at the prestigious @asco Annual Meeting. #biotechnology #oncology #clinicaltrial #immunotherapy #kras

Mythic Therapeutics, Inc. announced promising initial results from the Phase 1 KisMET-01 study of MYTX-011, a novel cMET-targeting ADC, in treating advanced or metastatic non-small cell lung cancer (NSCLC). The study, presented at the ASCO Annual Meeting, showed MYTX-011 was well-tolerated with no dose-limiting toxicity and demonstrated nearly dose-proportional pharmacokinetics. The study continues to assess safety, tolerability, and preliminary anti-tumor activity, with further efficacy data to be presented in the future. The findings offer hope for patients with diverse cMET expression levels. #HemiBio Brian Fiske https://lnkd.in/epvx2gPC

I am delighted to share the announcement of a #collaboration that I have initiated and will be leading on behalf of my client OregonTherapeutics trough my service Lab2BIOTECH. This collaboration involves the analysis of the #preclinical package of Oregon Therapeutics' lead product, XCE853, by Lantern Pharma Inc. (Nasdaq: LTRN) Pharma's #AI based RADR® platform, in order to identify the best clinical positioning of this #drug candidate for #Cancer patient's and further progress toward clinics together.  Please see the press release below. --- Personal notes: This is AI as I like it: no buzzwords, concrete analysis of huge datasets and literature points to leverage smarter strategies in #drugdevelopment and improve patient's impact. This collaboration is also a good illustration of my vision on how best to develop assets for startups. Licensing a drug candidate is not a final step at the end of a development plan. It's an ongoing process, starting from day one of project management, and requires open-mindedness, seeking out opportunities and collaborating with potential licensees to build trust and improve product-market fit with payers' expectations, while driving R&D forward.  Tip for founders: surround yourself!

BiVictriX Therapeutics plc (AIM:BVX, OTC:BVTXF), which is developing targeted treatments with fewer side-effects, said it had made significant progress with its BVX002 programme, targeting solid tumour indications with a focus on ovarian cancer. Specifically, it has successfully selected the final antibody sequences for BVX002, a first-in-class antibody drug conjugate (ADC), positioning it to identify a development lead in 2024. In preclinical models, BiVictriX has confirmed the efficacy and selectivity of these sequences. They demonstrate strong effectiveness against targeted cancer cells compared to non-target cells, passing early developability assessments. Emerging data, derived from primary patient samples using advanced sequencing techniques and laboratory profiling, indicate that the antigen fingerprint targeted by BVX002 is prevalent in various solid tumour types. More at #Proactive #ProactiveInvestors #AIM #OTC #BVX #BVTXF #BiVictriXTherapeutics http://ow.ly/Ux2X1054fHw

#FDA has granted #BreakthroughTherapy designation to Bayer's #BAY2927088, an investigational drug targeting non-small cell #lungcancer (#NSCLC) with specific #HER2 activating mutations. Patients with this mutation have limited treatment options, especially in the metastatic or advanced stages of the disease. BAY 2927088 is pioneering targeted cancer therapy as an oral, reversible tyrosine kinase inhibitor, focusing on mutant forms of HER2.  #FDAApproval ONCOLife https://lnkd.in/dpu2Sfh5

Mythic Therapeutics, Inc., a Hemi portfolio, presented promising preclinical data on MYTX-011, their innovative ADC therapy for cancer, at the AACR Annual Meeting. This investigational therapy targets cMET, showing increased internalization and cytotoxicity in tumor cells expressing moderate cMET levels. MYTX-011's pH-sensitive design allows for broader efficacy across various cMET expression levels, demonstrating potent cytotoxicity in multiple cancer cell lines and increased delivery of the payload in vivo. These findings suggest MYTX-011's potential as a versatile therapeutic candidate for a wide range of cMET-expressing malignancies, currently being evaluated in clinical trials for NSCLC. "We’re pleased to present data that highlight the potential of MYTX-011 as a therapeutic candidate for treating multiple types of solid tumors that express cMET," said Brian Fiske, Ph.D., Chief Scientific Officer and Co-founder of Mythic. #HemiBio https://lnkd.in/ePJnnUQX